Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy

By sjmartinez • September 19, 2024

Rovin BH, Ronco PM, Wetzels JFM, Adler SG, Ayoub I, Zaoui P, Han SH, Dudani JS, Gilbert HN, Patel UD, Manser PT, Jauch-Lembach J, Faulhaber N, Boxhammer R, Härtle S, Sprangers B. Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy. Kidney Int Rep. 2024 Jun 20;9(9):2635-2647. doi: 10.1016/j.ekir.2024.06.018. PMID: 39291206; PMCID: PMC11403052.

Tags: Clinical Trial, felzartamab, Harbor UCLA, MOR202, Nephrology, phase 2, phospholipase A2 receptor, primary membranous nephropathy, Publications

Gestational exposure to PM2.5, NO2, and sex steroid hormones: Identifying critical windows of exposure in the Rochester UPSIDE Cohort

Kahwaji M, Duttweiler L, Thurston SW, Harrington D, Miller RK, Murphy SK, Wang C, Brunner J, Ge Y, Lin Y, Hopke PK, O'Connor TG, Zhang[...]

Knowing Your ABCs: Macrophage ABCA1-Mediated Cholesterol Efflux as a Therapeutic Target in Atherosclerotic Cardiovascular Disease

Karpouzas GA, Ronda N. Knowing Your ABCs: Macrophage ABCA1-Mediated Cholesterol Efflux as a Therapeutic Target in Atherosclerotic Cardiovascular Disease. JACC Basic Transl Sci. 2024 Dec[...]

Risk Profile and Prognostic Implications of Premature Advanced Coronary Atherosclerotic Disease Among Young to Early Middle-aged Adults: The Coronary Artery Calcium Consortium

Boakye E, Dehesh M, Dardari Z, Obisesan OH, Osei AD, Dzaye O, Jha K, Rozanski A, Berman DS, Budoff MJ, Miedema MD, Nasir K, Rumberger[...]